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ABSTRACT Nucleophosmin (NPM)-1 is a multifunc-
tional protein involved in a variety of biologic processes
and has been implicated in the pathogenesis of several
human malignancies. To gain insight into the role of
isolated fragments in NPM1 activities, we dissected the
C-terminal domain (CTD) into its helical fragments. In
this study, we observed the unexpected structural be-
havior of thepeptide fragment corresponding tohelix (H)
2 (residues 264–277). This peptide has a strong tendency
to form amyloidlike assemblies endowed with fibrillar
morphology and b-sheet structure, under physiologic
conditions, as shown by circular dichroism, thioflavin T,
and Congo red binding assays; dynamic light scattering;
and atomic force microscopy. The aggregates are also
toxic to neuroblastoma cells, as determined using 3-(4;5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide re-
duction and Ca2+ influx assays. We also found that the
extension of the H2 sequence beyond its N terminus,
comprising the connecting loop with H1, delayed aggre-
gation and its associated cytotoxicity, suggesting that
contiguous regions of H2 have a protective role in pre-
venting aggregation. Our findings and those in the litera-
ture suggest that the helical structures present in the CTD
are important in preventing harmful aggregation. These
findings could elucidate the pathogenesis of acute mye-
loid leukemia (AML) caused by NPM1 mutants. Because
the CTD is not properly folded in these mutants, we hy-
pothesize that the aggregation propensity of this NPM1
region is involved in thepathogenesisofAML.Preliminary
assays on NPM1-Cter-MutA, the most frequent AML-CTD
mutation, revealed its significant propensity for aggrega-
tion.Thus, theaggregationphenomenashouldbe seriously
considered in studies aimed at unveiling the molecular
mechanisms of this pathology.—Di Natale, C., Scognami-
glio, P. L., Cascella, R., Cecchi, C., Russo, A., Leone, M.,
Penco, A., Relini, A., Federici, L., Di Matteo, A., Chiti, F.,
Vitagliano, L., Marasco, D. Nucleophosmin contains amy-
loidogenic regions that are able to form toxic aggregates
under physiological conditions. FASEB J. 29, 000–000 (2015).
www.fasebj.org
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NUCLEOPHOSMIN (NPM)-1 (ALSO KNOWN AS B23, No38, and
numatrin) is an abundantmultifunctional protein, initially
identified as a nuclear phosphoprotein, that constantly
shuttles between the nucleus and cytoplasm. It is present
in high quantities in the granular region of nucleoli (1, 2).
Three distinct isoforms have been reported to be
expressed in human cells: B23.1, the longest and the most
abundant (294 residues), is also the best characterized
isoform; B23.2 and B23.3 are splicing variants that lack the
C-terminal35aaanda29aa segment (residues 195–223) in
Abbreviations: AFM, atomic force microscopy; AML, acute
myeloid leukemia; ARF, alternate reading frame; CD, circular
dichroism; CR, Congo red; CSSP, contact-dependent secondary
structure propensity; CTD, C-terminal domain; DLS, dyna-
mic light scattering; DMF, N,N-dimethylformamide; Fmoc,
fluorenylmethoxycarbonyl; H, helix (with numbers 1–3);
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the basic region, respectively (3). Structural characteriza-
tions of B23.1 have shown that it is endowed with amodular
structure (Supplemental Fig. S1). The N-terminal domain,
also called the oligomerization domain, extends for approxi-
mately 100 residues and displays an 8-stranded b-barrel
fold. FiveN-terminal domains oligomerize to form a crown-
shaped homopentamer. Two or more of these pentamers
may associate to form decamers or higher oligomeric
species (4). A recent study has shown that this domain
exhibits structural polymorphism by populating conforma-
tional states ranging from a highly ordered and folded
pentamer to a highly disordered monomer and that the
monomer-pentamer equilibrium is modulated by post-
translational modifications, ionic strength, and protein
binding (5).
The central portion of NPM1 is characterized by the
presence of 2 acidic domains (residues 119–133 and
161–188) and a basic region (residues 198–239). These
domains although unstructured, are crucial for theDNA/
RNA recognition mechanism (6, 7). The C-terminal do-
main (CTD) encompasses residues 241–294 (Fig. 1). It
forms a globular structure consisting of a 3-helix bundle,
and for this reason it is also called the 3-helix-bundle do-
main (8). Atomistic NMR investigations have shown that 3
helices span residues 243–259 (H1), 264–277 (H2), and
280–294 H3). Secondary structure prediction analysis
indicates that the helical regions of the CTD are endowed
with a strong intrinsic propensity to adopt this particular
type of secondary structure (Supplemental Fig. S2A).
NPM1 has been the subject of several biophysical char-
acterizations focused on the stability of the full-length pro-
tein or of its isolated domains. These analyses have shown
that the N-terminal domain is endowed with a thermal and
chemical stability, with no unfolding observed when in-
creasing the temperature to 90°C or adding urea; by con-
trast, the CTD has been found to have a markedly lower
stability (9). Investigations of the CTD have provided a de-
tailed characterization of the complete folding pathway of
this domain (10–12). It folds via a compact transition state
characterized by an extended nucleus. Furthermore, these
studies have shown that the unfolded state is characterized
by malleable residual secondary structure at the interface
between the second and third helices and that a mutual
stabilization of the N- and the C-terminal-folded domain
occurs through a central intrinsically disordered region
(9–11, 13).
NPM1 belongs to the nucleophosmin/nucleoplasmin
family of proteins (14) and associates with DNA and RNA,
processes RNA, prevents misfolding and aggregation of
target proteins as a molecular chaperone, and mediates
chromatin assembly and disassembly as a histone chaper-
one (15, 16). The N-terminal domain is responsible for
its chaperone activities, whereas the C-terminal region
binds nucleic acids. The presence of several nuclear
and nucleolar import/export signals in the NPM1
sequence indicates the prominent role of NPM1 in
nuclear or nucleolar protein import; indeed, it is in-
volved in several biologic processes, such as ribosome
biogenesis, tumor suppression, and nucleolar stress
response (17, 18). This protein has been found to be
overexpressed in tumors of different histologic origin,
including gastric, ovarian, bladder, and prostate car-
cinomas and in various hematologic malignancies
(19–22). NPM1 also has been implicated in the apo-
ptotic response to stress and oncogenic stimuli (such
as DNA damage and hypoxia) (23) and can modulate
the activity and stability of crucial tumor-suppressor
proteins such as p53 (24). Loss of NPM1 function leads
to the destabilization and functional impairment of
the alternate reading frame (ARF) tumor-suppressor
pathway; thus, it acts as a positive regulator of ARF
protein stability (25).
NPM1 has been identified as the most frequently mu-
tated gene in acute myeloid leukemia (AML), accounting
for approximately 30% of cases (24, 26–30). The most
frequent human NPM1 mutations lead to variants with
altered C-terminal sequences of the CTD (Supplemental
Fig. S2A). These modifications, which involve the H3 re-
gion, lead to an unfolding of the CTD in the mutated
protein (8, 11) and its accumulation in the cytoplasm,
caused by the loss of nuclear localization sequences with
mutations of Trp290 (MutE) and also of Trp288 (MutA)
(8, 31). Indeed, most NPM1 mutations result in critical
changes in the CTD, interfering with its nucleolus-
cytoplasm trafficking and leading to the aberrant accu-
mulation of the protein in the cytoplasm of the leukemic
cells (thus, the term NPM cytoplasmic positive: NPMc+
AML) (29). The cytoplasmic dislocation of NPM1 appears
to be critical to its leukemogenic activity; thus, the in-
creased NPM1 export into the cytoplasm affects multiple
cellular pathways andmay drive leukemia by either loss- or
Figure 1. Ribbon structure of NPM1-CTD (residues 241–294).
Fragments derived from secondary structure dissection of the
3-helix bundle are outlined in red (H2264–277), blue (the
N-terminal extension reported in sequences Nterm H2
extended259–277 and N-, C-term H2 extended259–280), and cyan
(the C-terminal extension reported in sequences Cterm H2
extended264–280 and N-, C-term H2 extended259–280). Protein
Data Bank code, 2VXD (8).
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gain-of-functionmechanisms. The dislocation of NPM1 in
the cytoplasm causes the loss of function of this normally
nuclear protein, andNPM1 interactors can be delocalized
into the cytoplasm by NPM1c+ and their activity signifi-
cantly impaired. In addition, NPM1 mutants acquire new
properties, such as the ability to interact and inhibit the
cell death activity of caspase-6 and -8 in the cytoplasm(32).
Because the primary sequences of the 3 helices con-
tained in NPM1-CTD share a high propensity to form
a-helical structures (Supplemental Fig. S2B) (9), we dis-
sected this domain into peptides corresponding to these
helices to gain insight into their conformational behavior
and their ability to interact with NPM1 biologic partners.
Fragments corresponding to the H1 and H3 regions as-
sumehelical states (7) (unpublished results). In this study,
the unexpected behavior of H2 is described: we seren-
dipitously found that the fragment corresponding to the
H2 region (hereafter denoted as H2264–277) spontane-
ously forms stable and cytotoxic aggregates under physi-
ologic conditions.
These aggregates appear to be amyloidlike assemblies
endowedwith fibrillarmorphology andb-sheet structure
and an ability to bind amyloid-diagnostic dyes. A pre-
liminary characterization of the CTD bearing the most
common AML mutation, NPM1-Cter-MutA, indicated
a significant propensity to aggregate. The biologic impli-
cations of these findings for NPM1 functions and mal-
functions are also discussed.
MATERIALS AND METHODS
Peptide synthesis
Reagents for peptide synthesis were from InBios (Naples, Italy).
Solvents for peptide synthesis and HPLC analyses were from
Romil (Dublin, Ireland); reversed-phase (RP) columns for pep-
tide analysis and the liquid chromatography-mass spectrometry
(LC-MS) system were from Thermo Fisher Scientific (Waltham,
MA, USA). Solid-phase peptide syntheses were performed on an
automated multichannel synthesizer Syro I (MultiSynTech,
GmbH,Witten,Germany). PreparativeRP-HPLCwasperformed
on anLC-8A equippedwith an SPD-M10AVdetector (both from
Shimadzu, Kyoto, Japan) and aC18 Jupiter column(503 22mm
inner diameter; 10 mm; Phenomenex, Castel Maggiore, Italy).
LC-MS analyses were performed on an LCQDECAXP Ion Trap
mass spectrometer equipped with an Opton Educational
Services, Inc. source, operating at 4.2 kV needle voltage and
320°C, with a complete Surveyor HPLC system, comprising an
MS pump, an autosampler, and a photo diode array (all from
Thermo Fisher Scientific). The peptides reported in Table 1
were synthesized by following standard fluorenylmethox-
ycarbonyl (Fmoc) strategies on a 50 mmol scale (33). To better
mime theprotein regions, thepeptides investigated in this study
were acetylated and amidated at the extremities. Rink-amide
resin (substitution, 0.5 mmol/g) was used as the solid support.
Activation of the amino acids was achieved with 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafuorophosphate
(HBTU)/1-hydroxy-benzotriazole (HOBt)/di-isopropylethylamine
(DIEA) (1:1:2), whereas Fmoc deprotection was performed with
a 20%(v/v)piperidine solution inN,N-dimethylformamide (DMF).
Peptides were removed from the resin by treatment with a TFA:tri-
isopropylsilane (TIS):H2O (90:5:5 v/v/v) mixture for 90 min at
room temperature. The crude peptides were then precipitated in
cold ether, dissolved in a water/acetonitrile (1:1 v/v) mixture, and
lyophilized.
Products were purified by RP-HPLC, applying a linear
gradient of 0.1% TFA CH3CN in 0.1% TFA water from 5–65%
over 12 min with a semipreparative 2.23 5 cm C18 column at
a flow rate of 20 ml/min. Peptide purity identity was con-
firmed by LC-MS. Purified peptides were lyophilized and
stored at 220°C until use.
Protein expression and purification
The coding sequence for NPM1-Cter-MutA, corresponding to
residues 225–298 of themost commonAML-associatedmutant
of NPM1 (26), was obtained through gene synthesis and
cloned in a pGEX6P1 expression vector. NPM1-Cter-MutA was
expressed from Escherichia coliBL21(DE3) cells and purified to
homogeneity (30).
Far-UV circular dichroism spectroscopy
Samples were prepared by dilution of freshly prepared stock
solutions (2 mM peptide on average), with peptide concen-
trations determined by UV absorbance with an e275 value of
1390 cm21 M21. Circular dichroism (CD) spectra were recorded
on a J-815 spectropolarimeter (Jasco, Tokyo, Japan), registered at
25°C in the far-UV region from 190 to 260 nm. Other experi-
mental settings were 20 nm/min scan speed, 2.0 nm band width,
0.2 nm resolution, 50 mdeg sensitivity, and 4 s response. Each
spectrum was obtained with an average of 3 scans, subtracting
contributions from corresponding blanks and converting the
signal to mean residue ellipticity ([Q]res) in units of degrees per
square centimeter per decamole (deg cm2 dmol21). The peptide
concentrationwas 50or 100mM, and a 0.1 cmpath-length quartz
cuvette was used. For H2 short265–272 and H2 very short268–272,
CD spectra were registered at 200 and 500 mM, respectively. For
TABLE 1. Sequences of peptides based on H2 of the NPM1-CTD
Name Sequence MW (amu) pI
H2264–277 264VEAKFINYVKNCFR277 1744.0 9.19
K-H2263–277 263KVEAKFINYVKNCFR277 1901.2 9.63
PK-H2262–277 262PKVEAKFINYVKNCFR277 1998.3 9.65
Nterm H2 extended259–277 259GSLPKVEAKFINYVKNCFR277 2255.6 9.63
Nterm H2 ext. mutated259–274 259GSLPKVEAKFARLSIM274 1789.1 9.99
Cterm H2 extended264–280 264VEAKFINYVKNCFRMTD280 2120.4 8.15
N-, C-term H2 extended259–280 259GSLPKVEAKFINYVKNCFRMTD280 2603.0 9.11
H2 short265–272 265EAKFINYV272 1026.1 6.10
H2 very short268–272 268FINYV272 696.7 5.52
MW (amu), molecular weight (atomic mass units).
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NPM1-Cter-MutA, CD spectra were registered at 11 mM with
a 0.2 cm path-length quartz cuvette. CD spectra were acquired in
various buffers: 10 mM formiate (pH 3), 10 mM acetate (pH 5),
10 mM phosphate (pH 7), and 10 mM borate (pH 10).
Temperature-dependent spectra were registered in the range
of 298–368 K with a Peltier temperature controller.
Thioflavin T fluorescence assay
The thioflavin T (ThT) solution (6.48 ml; 38.5 mM in water) was
added to 2.5 ml of the peptide stock solutions (the final concen-
trationsofThTandpeptideswereboth100mM),whereas forNPM1-
Cter-MutA, similar spectrawere recordedat16and20mM,while the
concentration of ThT was 20 mM at 25°C. ThT fluorescence was
measured with a Varian Cary Eclipse spectrofluorimeter (Agilent
Technologies, Stamford, CT, USA) and a quartz cuvette cell of
10 mm path-length, with magnetic stirring. Measurements were
collected every 1–5 min for 60–240 min, and for NPM1-Cter-MutA
until 13 days, with excitation and emission wavelengths of 440
and 450–600 nm, respectively.
Congo red absorbance assay
InteractionofCongo red (CR)with peptide aggregates was tested
with a NanoDrop 2000, UV-Vis Spectrophotometer (Thermo
Fisher Scientific) by recording the absorbance spectra from
400–800 nm with a 10 mm quartz cell. H2 peptides at 500 mM
concentration and buffer as the control were incubated in 5 mM
NaH2PO4 (pH 7.4) at 25°C, and an aliquot of 60 mL of each
samplewasmixedwith 440ml of a 5mMNaH2PO4, 150mMNaCl
buffer (pH 7.4), containing 20 mM CR. Spectra were then
recorded. The difference spectrum obtained by subtracting the
spectrum of CR alone from that of CR+ peptide indicated the
spectrum of CR bound to the b-sheet structure.
Light-scattering measurements
H2264–277 and Nterm H2 extended259–277 (250 mM and 5 mM
monomer concentrations, respectively) were kept in 10 mM
borate buffer (pH 10) at 25°C, with constant stirring. The
measurements were performed with a Zetasizer Nano S dy-
namic light-scattering (DLS) device (Malvern Instruments,
Worcestershire,United Kingdom)with a 633 nm laser, in dual-
scattering-anglemode, thermostatedwith a Peltier system, and
a low-volume (45 ml), ultramicrocell. Size distributions by in-
tensity and total light-scattering intensity were determined
in automatic mode at regular time intervals over a period of
10 min for each measurement. Parameters were 13 acquis-
itions, each of 10-s duration.
AFM
H2264–277 and Nterm H2 extended259–277 peptides were in-
cubated in 10 mM borate (pH 10) at 22°C. For AFM inspection,
sample aliquots of 10mLwere extracted at different times during
the aggregation reaction. Each aliquot was diluted 10-fold, and
10 mL of the diluted sample was deposited on a freshly cleaved
mica substrate and dried in a mild vacuum. Tapping Mode AFM
images were acquired in air with a Veeco Dimension 3100
Scanning Probe Microscope, equipped with a G scanning head
(maximum scan size, 100 mm), and driven by a Nanoscope IIIa
controller (Bruker, Billerica, MA, USA), and with a Multimode
Scanning Probe Microscope equipped with an E scanning head
(maximum scan size, 10 mm), driven by a Nanoscope V con-
troller (Bruker). Single-beam uncoated silicon cantilevers (type
OMCL-AC160TS; Olympus, Tokyo, Japan) were used. The drive
frequency varied between280 and 330 kHz, and the scan rate was
between 0.2 and 0.8 Hz. Aggregate size was determined by the
height in cross section of the topographic AFM images.
Cell cultures
Human SH-SY5Y neuroblastoma cells (American Type Culture
Collection, Manassas, VA, USA) were cultured in DMEM/F-12
Ham’swith25mMHEPESandNaHCO3(1:1)and supplemented
with 10% fetal bovine serum, 1.0 mM glutamine, and antibiotics.
Cell cultures were maintained in a 5.0% CO2 humidified atmo-
sphere at 37°C and grown until they reached 80%confluence for
a maximum of 20 passages.
MTT reduction assay
SH-SY5Y cells were seeded in 96-well plates. Aggregates of
H2264–277, NtermH2 extended259–277, H2 short265–272, and H2 very
short268–272 were incubated at concentrations of 100 mM (first
2 peptides) and 400 mM (last 2 peptides) in 10 mM borate buffer
(pH 10) at 25°C, for 0, 1, and 15 h. The samples were centrifuged
to collect the aggregates, which were resuspended in cell culture
medium, all at a 100 mM peptide concentration, and then added
to theSH-SY5Ycells for 24hat 37°C.Cell viabilitywas thenassessed
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) reduction assay (34). In brief, the cell cultures were
washed and incubated with 0.5 mg/ml MTT solution at 37°C for
4 h, and subsequently with cell lysis buffer (20% SDS, 50% DFM,
pH 4.7) at 37°C for 3 h. Absorbances of blue formazan were
determined at 590 nm, and cell viability was expressed as the
percentage of MTT reduction in treated cells compared to
that in untreated cells (taken as 100%).
Measurement of intracellular Ca2+
Aggregates ofH2264–277, NtermH2 extended259–277, H2 short265–272,
and H2 very short268–272 were incubated at concentrations of
100 mM (first 2 peptides) and 400 mM (last 2 peptides) in
10 mM borate buffer (pH 10) at 25°C for 0, 1, and 15 h. The
samples were centrifuged to collect the aggregates, which were
resuspended in cell culture medium, all at a 100 mM peptide
concentration, and then added to SH-SY5Y cells seeded on glass
coverslips for 60minat37°C.Thecellswere then loaded for30min
at 37°C with 10 mM fluo3-AM (Life Technologies, Carlsbad, CA,
USA) and 0.01% (w/v) pluronic acid F-127 in HBSS and sub-
sequently fixed in 2% buffered paraformaldehyde for 10 min at
room temperature. The resulting cell fluorescence was analyzed
with a confocal scanningmicroscope (TCSSP5; Leica,Mannheim,
Germany) equipped with an argon laser source for fluorescence
measurements at 488 nm and a Plan Apo 363 oil-immersion
objective (Leica). A series of optical sections (10243 1024 pixels)
1.0 mm in thickness was taken through the cell depth for each
examined sample. The confocal microscope was set at optimal
acquisition conditions (e.g., pinhole diameters, detector gain,
and laser powers). The settings weremaintained constant for each
analysis. To quantify the signal intensity of the fluorescent probe,
between 10 and 22 cells were analyzed with ImageJ software
(National Institutes of Health, Bethesda, MD, USA), and the
fluorescence intensities were expressed as arbitrary units.
Statistical analysis
Data are expressed as means6 SEM. Comparisons between the dif-
ferent groupsweremadebyANOVA followedbyBonferroni’s post-
comparison test. P, 0.05 was considered statistically significant.
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RESULTS
On the basis of the sequence corresponding to the H2
region of the NPM1-CTD, 9 different peptides were syn-
thesized and characterized. Most of the analyses were
conducted on the fragment corresponding to the region
264–277 (H2264–277), which constitutes H2 in the NMR
structure of NPM1 (Fig. 1). Several longer and shorter
variants of this prototypal peptide were also investigated.
The sequences of all peptides are reported in Table 1. To
properly mime the behavior of these regions in the real
protein, all peptides were acetylated and amidated at the
N and C termini, respectively. They were chemically
synthesized with good yields by solid-phase peptide syn-
thesis, by using Fmoc methodologies, and were purified
by RP-HPLC. Their identity and purity (averaged purity,
.97%) were assessed by LC-MS (data not shown).
The H2264–277 peptide forms amyloidlike aggregates in
physiologic conditions
A freshly dissolved solution of the H2264–277 peptide in
10mMphosphate buffer (pH7), exhibited a characteristic
b-sheet far-UV CD spectrum with a broad minimum at
218 nm (Fig. 2A). The spectrum was virtually unchanged
within24h, except for a slightdecrease in theoverall signal,
probably resulting from the formation of large aggregates
that escaped experimental detection. The large mean
residue ellipticity (in the 215–220 nm range) indicated
a b-sheet content similar to that of amyloid fibrils (35).
The conformational behavior of H2264–277 was also
evaluated as a function of pH. In 10 mM borate buffer at
pH 10, the far-UV CD spectrum was identical with that
registered at pH 7 (Fig. 3A). In contrast, spectra collected
at acidic pH, in 10 mM citrate buffer (pH 3) and 10 mM
acetate buffer (pH 5), presented distinctive features: they
were characterized by the presence of a minimum at
;207 nm and a shoulder at;222 nm. These features are
indicativeof amixtureof conformational states (i.e., random
coil and a helix; Supplemental Fig. S3A).
The influence of pH on the conformational properties
may be explained by considering the charge distribution in
the peptide sequence. At acidic pH, the highly positive net
chargeof thepeptideprevented thenearingof themolecules
that leads to aggregation, whereas at neutral or basic pH, the
positive charge was attenuated or cancelled, leading the
peptide to self-assemble into b-sheet-containing aggregates.
The influence of the temperature onH2264–277 structure was
also examined: b-structure-like CD spectra appeared stable
upon the increase of temperature in the range 298–368 K,
suggesting the presence of stable aggregates (Supplemental
Fig. S4A). This is the typical behavior of an aggregated b
structure that does not unfold at high temperature.
To gain insight into the propensity of H2264–277 to ag-
gregate, the time course of ThT fluorescence intensity in
the presence of a freshly prepared solution of the peptide
wasmonitored at 100mMand pH10with stirring. ThTwas
chosen as themost common diagnostic dye of amyloidlike
aggregates (36). The time dependence of the ThT fluo-
rescence is generally suggestive of a nucleation-dependent
growthmechanism that is typical for thekinetics of amyloid
fibril formation. The aggregation of H2264–277 showed this
behavior but took place very quickly with a lag phase close
to 0 (Fig. 4A, Table 2). In addition, the ThT fluorescence
was significantly high at time 0 [(;10 arbitrary units (au)],
indicating that the peptide was aggregating, even at the
start of the registered time course.
We also used the CR assay to assess whether H2264–277
displays typical amyloid properties. Peptide concentration
Figure 2. Overlay of CD spectra, recorded at 0, 2, 4, and 24 h from a fresh sample preparation, of (A) H2264–277, (B) K-H2263–277,
(C) PK-H2262–277, (D) Nterm H2 extended259–277, (E) Cterm H2 extended264–280, (F) N-, C-term H2 extended259–280, and (G)
Nterm H2 extended mutated259–274, in 10 mM phosphate buffer (pH 7).
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was 500 mM, and pH was 7.4 in this case. The CR absor-
bance increased in the presence of the H2264–277 peptide,
and the wavelength of maximum absorption red shifted
from 490 to 510 nm (Fig. 4G). The difference spectrum
with a maximum at 550 nm indicated the presence of or-
dered aggregates with a b-sheet structure (Fig. 4H).
The extension of the H2 sequence limited its tendency
to form amyloidlike aggregates
To investigate the role of the amino acid residues adjacent
toH2 on the aggregation tendency of this CTD region, we
designed and characterized longer variants by extending
both its N- and C-terminal ends. In particular, at the N
terminus we progressively added the residues of the region
connecting H1 and H2 (i.e., residues 259–263). At the C
terminus, the 3 residues 278–280 connecting H2 to H3
were added (Table 1).
The CD spectra showed that the addition of Pro262 and
Lys263 did not have a significant effect on the aggregation
properties of H2 (Fig. 2B, C). In contrast, the addition
of the fragment GSL259–261 delayed the formation of
the b-sheet structure (Fig. 2D). Indeed, in contrast
to H2264–277, the freshly dissolved Nterm H2
extended259–277 peptide at pH 7 presented a CD spec-
trum characterized by a minimum at ;205 and a shoul-
der at 222 nm. These features are suggestive of a mixture
of different secondary structure conformations. The
evolution of the CD spectrum over time clearly indicated
an enrichment of the b-structure content. Indeed a shift
of the minimum from 205 to 213 nm occurred while the
shoulder at;222nmdisappeared. A similar behavior was
shown at pH 10, although this conformational transition
appeared to be more rapid (Fig. 3B).
The addition of 3 residues at the C terminus did not
substantially influence the tendency of H2 to aggregate: in
particular, the CD spectra of CtermH2 extended264–280
at neutral pH indicated a b transition in 2 h (Fig. 2E), and
those at pH 10 indicated the presence of b-sheet aggre-
gates, even at time 0 (Fig. 3C).
However, the concurrent extension at both the N and C
termini clearlydelayed theaggregation: evenafter24h, the
CDspectrumofN-,C-termH2extended259–280maintained
featuresof amixture of secondary structure conformations
at both pH 7 and 10 (Figs. 2F, 3D).
In the ThT fluorescence assay, the time course of
Nterm H2 extended259–277 aggregation (Fig. 4B) at pH 10
presented a kinetic profile similar to that exhibited by
H2264–277 (Fig.4A).However, thepresenceof theN-terminal
extension delayed aggregationwith respect toH2: the initial
ThT fluorescence was lower than that observed for
H2264–277, a lag-phase of ;30 min was present, and the in-
crease in ThT fluorescence was found to be slower, with
a weak fluorescence, even after 160 min (Fig. 4B). The CR
assay, performed after 1 d of incubation at pH7.4, indicated
spectral features for Nterm H2 extended259–277 similar
to those exhibited by H2264–277 (Fig. 4G, H).
Similar to its effect onH2264–277, an acidic pH condition
did not cause substantial conformational transitions in any
of the extended peptides (Supplemental Fig. S3B–G) and
completely prevented peptide aggregation in the ThT as-
say (Fig. 4C).
Analysis of H2 aggregates by DLS and AFM
TheaggregationofH2peptideswas further investigatedby
means of DLS (Fig. 5A). A freshly prepared solution of
H2264–277 at pH 10 revealed the presence of aggregated
Figure 3. Overlay of CD spectra recorded at 0, 2, 4, and 24 h from a fresh sample preparation of (A) H2264–277, (B) Nterm H2
extended259–277, (C) Cterm H2 extended264–280, (D) N-, C-term H2 extended259–280, (E) Nterm H2 extended mutated259–274, and
at 0, 1, 4 and 12 h for (F) H2 short265–272, and (G) H2 very short268–272 in 10 mM borate buffer (pH 10).
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species. The analysis of the size distribution by the light-
scattering intensity of the aggregated peptide showed 2
peaks centered at hydrodynamic diameters of ;50 nm
(themost populated) and;300 nm, respectively. After 4 h
under stirring, the sample appeared cloudy. In another
experiment, the same samplewas immediately treatedwith
hexafluoroisopropanol, which is a known disaggregating
solvent of b-like structures (37), for 30 min at a concen-
tration of 50% (v/v). After the removal of the organic
solvent by evaporation, theDLS analysis of the solution did
not show the presence of aggregates, as expected for
a monomeric 13-mer peptide, with a hydrodynamic di-
ameter that is probably less than the size limit of the in-
strument. These experiments confirmed that freshly
prepared samples of H2264–277 contain aggregates, as ob-
served in the CD and ThT analyses.
Freshly dissolved Nterm H2 extended259–277 at pH 10
displayed a different behavior, as the DLS analysis did
not show the presence of any aggregate. Only after 30 h
with stirring did the sample contain aggregates, with an
intensity of scattering that showed 3 main peaks of hy-
drodynamic diameters centered at 30, 100, and 400 nm.
(Supplemental Fig. S5A).
Tapping Mode atomic force microscopy (AFM; Bruker)
was used to monitor the aggregation of H2264–277 and
NtermH2extended259–277peptides in10mMborate(pH10).
TheH2264–277 peptidewas found toundergo rapid aggregation.
Fibrillar aggregates were detected at the start of the exper-
iment (not shown). At longer aggregation times, large
clusters offibrils wereobserved, withfibrils forming a closely
intertwinedmesh (Fig. 5B) Thefibril height increased from
3.1 6 0.2 nm at time (t) = 0 to 7.3 6 0.4 nm at t = 30 min
Figure 4. ThT and CR assays for the H2-based peptides. Time course of ThT fluorescence emission intensity at 480 nm for (A)
H2264–277 and (B) Nterm H2 extended259–277 at pH 10; (C) Nterm H2 extended259–277 at pH 5; and (D) Nterm H2 extended
mutated259–274, (E) H2 short265–272, and (F) H2 very short268–272 at pH 10. All assays at 100 mM peptide concentration. G)
Absorbance spectra of H2264–277+CR, CR, and Nterm H2 extended259–277+CR. (H) Difference absorbance spectra obtained for
H2264–277 and Nterm H2 extended259–277.
TABLE 2. Aggregation kinetics of peptides based on H2 of the
NPM1-CTD at pH 10
Name Lag time (min)
H2264–277 0
Nterm H2 extended259–277 30
H2 short265–272 22
H2 very short268–272 0
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and 9.5 6 0.5 nm after 1 h aggregation. The Nterm H2
extended259–277 peptide displayed slower aggregation than
H2264–277. The fibrils were longer (Fig. 5C), and the fibril
height did not change significantly with the aggregation
time, being 3.76 0.7 nm in the early stages of aggregation
and 3.3 6 0.4 nm after 10 h. For both peptides, the fibril
morphologies and sizes are compatible with those com-
monly observed in amyloidlike aggregates.
The mutation of the H2 sequence suppressed its
tendency to form amyloidlike aggregates
The role of the C-terminal region ofH2 in the aggregation
process was also investigated by the analysis of a peptide
fragment generated from an NPM1 variant reported for
AML with normal karyotype patients (38). This mutant is
characterized by the deletion of the last 20 residues of the
protein, beyond the H2 region, and by a completely dif-
ferent sequence for the 269–274 region, within H2
(Table 1). Because in this variant most of the residues of
the pentapeptide, which likely represents the core of H2
aggregates, are changed, we evaluated the impact of these
disease-associated modifications through the character-
ization of the fragment 259–274 of this form (Nterm H2
extended mutated259–274). CD spectra collected over time
for the peptide at both pH 7 and 10 indicated that it
preferentially adopted a random coil structure in solution
with a residual, albeit small, a-helical structure (Figs. 2G,
3E).No conversionof these conformers toward theb-sheet
structure was detected in the explored time interval. Fur-
thermore, theNtermH2 extendedmutated259–274 peptide
was not able to aggregate, because the ThT fluorescence
signal did not increase over time, at pH 10 (Fig. 4D).
The pentapeptide 268–272, sequence FINYV, is the
minimum H2 fragment that forms aggregates
Theprimary sequence of theNPM1-CTDwas used as input
to predict its tendency to form amyloidlike aggregates by
using the PASTA server (http://protein.bio.unipd.it/pasta2/;
University of Padua, Padua, Italy). This analysis unveiled
that theH2 regionhas a strong intrinsic propensity to form
amyloidlike aggregates and that the core of these aggre-
gates corresponds to fragment 265–272, sequence EAK-
FINYV (Fig. 6A). It is alsoworthnoting that the sequenceof
theH2 region has a versatile conformational behavior, as it
showed a tendency to adopt different states (a helix and b
sheet) according to the NetCSSP (contact-dependent
secondary structure propensity) server (39) (Fig. 6B).
According to these predictions, we sought to identify the
shortest H2 fragment that forms amyloidlike assemblies.
Therefore, experiments similar to those performed with
H2264–277 at pH 10 were performed on the fragment
265–272 EAKFINYV (H2 short265–272). The CD spectra of
this peptide at pH 10 appeared quite different over time;
indeed, the freshly prepared sample provided a helicallike
CD-spectrum that after 12 h presented only a broad mini-
mumat 210nm(Fig. 3F).This behavior is supportedby the
observation that the fragment displays a good propensity
for adopting either an a-helical or a b-sheet conformation
(Fig. 6B). However, this peptide had a strong tendency to
aggregate and precipitate, as shown by the relatively fast
CD signal decrease over time (Fig. 3F). The formation of
amyloidlike aggregates by this peptide was confirmed by
the ThT assay (Fig. 4E).
The sequence of H2 short265–272 was characterized by
the presence of charged amino acid residues at its N ter-
minus and a hydrophobic stretch at the C terminus. We
therefore evaluated the ability of the hydrophobic penta-
peptide FINYV to aggregate independently (H2 very
short268–272). The analysis of the CD spectrum at pH 10
clearly indicated that this fragment had a strong tendency
to form b-sheet aggregates (Fig. 3G). Notably, the struc-
tural features of this peptide did not show any significant
variation in the temperature range 298–368 K (Supple-
mental Fig. S4B). Moreover, H2 very short268–272 showed
a great propensity to form amyloid aggregates, as shown
by the ThT assay, with faster kinetics than those of H2
short265–272 (Fig. 4F, Table 2).
H2-derived peptides induce cytotoxicity and
intracellular Ca2+ influx in SH-SY5Y cells
The H2-derived peptides were also evaluated for their
ability to impair cell viability. We first analyzed the effects
Figure 5. A) DLS intensity analysis of freshly prepared H2264–277 oligomeric sample (monomeric concentration was 250 mM). B,
C) Tapping Mode AFM images (height data; Bruker) of fibrillar aggregates formed by (B) H2264–277 and (C) Nterm H2
extended259–277 in 10 mM borate (pH 10), after (B) 1 and (C) 5 h. Scan size, 1.5 mm; Z range, (B) 110 and (C) 12 nm.
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of the aggregates formed from the H2 peptides on the
mitochondrial status by measuring the MTT reduction
assay in human SH-SY5Y neuroblastoma cells. Samples
from H2264–277, Nterm H2 extended259–277, H2
short265–272, and H2 very short268–272 were incubated at
a monomer equivalent concentration of 100 mM at 3 dif-
ferent times (0, 1, and 15 h) and then added to the cells.
Aggregates of H2264–277 showed the highest toxicity at
0 and 1 h, becoming almost ineffective after 15 h of in-
cubation (Fig. 7), whereas aggregates of Nterm H2
extended259–277 showed the main toxicity after 15 h of
incubation. Aggregated H2 short265–272 and H2 very
short268–272 were found to be toxic both at the short and
long times, although the toxicity was slightly lower at 15 h,
relative to the earlier times. The decrease in toxicity with
aggregation time for H2264–277, H2 short265–272, and H2
very short268–272probably arises fromthe conversionof the
early aggregates into larger aggregates or mature fibrils,
which are known to be less toxic than the first oligomeric
species (40–43). By contrast, the increase in toxicity
with aggregation time observed for the Nterm H2
extended259–277 peptide is likely to result from the slower
aggregation process of this peptide. The comparison
between the toxicities found at 0 and 1 h indicates that
the extended and shortened versions of the H2 peptides
are less and more toxic than H2264–277, respectively.
It is widely accepted that disruption of intracellular
Ca2+ homeostasis is one of the earliest biochemical con-
sequences of the interaction of prefibrillar aggregates with
cell membranes (44, 45). We therefore investigated the
effects of aggregated H2 peptides on the Ca2+ content of
SH-SY5Y cells. Aggregates of H2264–277 were found to cause
a large influx of extracellular Ca2+ ions into the cytosol at
the 0 and 1 h aggregation times, becoming less toxic after
15 h (Fig. 8). By contrast, aggregates of Nterm H2
extended259–277 were weakly toxic at 0 and 1 h and caused
the main Ca2+ influx after 15 h of aggregation time.
Aggregates ofH2 short265–272 andH2 very short268–272 were
found to lead to a strong increase in intracellular Ca2+, at
both the short and long times, although the effect was less
marked at 15 h. Overall, the Ca2+ influx caused by the ag-
gregated peptides showed a trend similar to that observed
for the MTT reduction assay (Fig. 7). Hence, the compar-
ison between the effects found at 0 and 1h indicate that the
extended and shortened versions of the H2 peptides were
less and more toxic than H2264–277, respectively.
Figure 6. Prediction of (A) amyloidlike aggregation determined using PASTA. (B) Chameleon profile using NetCSSP of
NPM1-CTD.
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NPM1-Cter-MutA tends to slowly aggregate
We purified the CTD of themost common AML-associated
mutant of NPM1 (26), corresponding to residues 225–298
of the mutated NPM1 protein (NPM1-Cter-MutA). ThT
fluorescence spectrawere registeredatdifferent timepoints
in the presence of NPM1-Cter-MutA at 16 mM, with stirring
(pH 10). This analysis revealed a progressive increase in
fluorescence intensity within 13 d, suggesting a rather slow
formation of amyloidlike species (Fig. 9A). This trend was
confirmed by similar experiments performed at the slightly
higher concentration of 20 mM (data not shown).
Furthermore, CD analysis over 8 d with constant stirring
(pH 10) revealed that NPM1-Cter-MutA tended to aggre-
gate, suggested by the progressive decrease in CD signal
intensity over time (Fig. 9B).
A deeper analysis of the overlay of CD spectra registered
at different times did not show significant variations of the
overall shapeof the spectrum(i.e., locationof theminima).
This finding suggests that the protein region involved in
the aggregation process is rather limited.
DISCUSSION
The CTD of NPM1 is an essential element for the activities
of this multifunction protein. It is crucial for shuttling and
for its interactions with DNA (6, 23, 31), and its function-
ality relies on the specific fold that it adopts: a 3-helix
bundle. Investigations have indicated that the 3 helical
regions of the domain are endowed with a high intrinsic
propensity for this structural element (9, 12).Nevertheless,
the results in this study show that, inphysiologic conditions,
the fragment corresponding to thea-H2 formsamyloidlike
cytotoxic aggregates. A posteriori bioinformatics analyses
confirm the chameleonic nature of this region.
The inspection of the sequence highlights the presence
of several charged residues that usually hamper the for-
mation of amyloidlike aggregates. The longest fragment
that maintains a significant tendency to form b-structured
aggregates (Nterm H2 extended259–277) presents a basic
isoelectric point (pI), due to the presence of 3 lysine and 1
arginine residues and a single glutamic acid residue. This
observationexplains the increased tendencyof thepeptide
to form b-structured aggregates when the pH is shifted
from 3 or 5 (no aggregation), to 7 (very slow aggregation),
to 10 (slow aggregation). Indeed, the reduction of the
overall positive charge of the peptide from pH 7 to 10,
which is due to the full or partial deprotonation of the
positively charged residues, favors aggregation, whereas
the further accumulation of positive charges from pH 7 to
acidic pH values inhibit self-assembly.
Nevertheless, the ability of the H2264–277, K-H2263–277,
and PK-H2262–277 peptides to readily aggregate into a b
structure at pH 7 indicates that the formation of this
assembly is compatible with the presence of several
charged residues. In a putative aggregate formed by the
packing of 2 adjacent b sheets, it is unlikely that these
charged residues are inserted in the dry interface of the
interacting b sheets. By considering that, in a b strand,
the positioning of the side chains alternates with respect
to the backbone, the analysis of the specific sequence of
this fragment shows an intriguing finding: that all
charged residues are positioned on the same face of the
sheet. If we assume that this is an external face of a 2-sheet
aggregate, the dry core of this b structure likely involves
some or all of the following residues: Val264, Ala266,
Phe268, Asn270, Val272, Asn274, and Phe276. It is important
to note that these types of residues are frequently found
at the dry interfaces of the steric zipper assemblies
characterized by Eisenberg et al. (46, 47).
Present data show that the extension of the N- and C-
terminal endsof theH2peptide, to include the connecting
regions with H1 and H3, delays its aggregation. The most
evident effect is produced by the inclusion of the GSL
(259–261) trait at theN terminus. The apolar side chain of
Leu261,whichalso formshydrophobic interactionswith the
Tyr271 side chain in the folded 3-helix bundle (Protein
Data Base code 2VLD; maintained by the Research Col-
laboratory for Structural Bioinformatics; http://www.rcsb.
org/pdb/static.do?p=general_information/about_pdb/
index.html), establishes interactions with the numerous
apolar side chains of thepeptide,disfavoring theprocess of
formation of the b-structured assembly. In addition, both
Gly259 [intrinsically low propensity to adopt b structure
(48)] andSer260 for itspolarity (49) are alsounconstructive
for b-sheet aggregation. These considerations add to the
presence of Pro262 and Lys263, which are a b-breaker (50)
and a charged residue, respectively, and further increase
the net charge.
Figure 7. Cytotoxicity of aggregates formed by H2 peptides.
Aggregates of H2264–277, Nterm H2 extended259–277, H2
short265–272, and H2 very short268–272 (100 mM monomer
concentration) were formed at 3 different times (0, 1, and
15 h) and added to human SH-SY5Y neuroblastoma cells. Cell
viability was expressed as the percentage of MTT reduction in
the treated cells, compared with that in the untreated cells
(taken to be 100%). The values shown are means 6 SEM of
results in 3 independent experiments performed in triplicate.
*P # 0.05, **P # 0.01, ***P # 0.001 vs. untreated cells, unless
otherwise indicated.
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These observations suggest that the local context has
an impact on the aggregation tendency of H2 and have
implications for the aggregation propensity of the en-
tire CTD. It has been reported that the thermally
and chemically denatured states of NPM1-CTD retain
significant residual structure mainly at the interface
between H2 and H3 (10, 11) and that this compact
denatured state is stable over time (9–11). Our
experiments show that the wild-type (wt) CTDofNPM1
does not possess any tendency to aggregate (data not
Figure 8. Representative confocal scanning microscope images showing intracellular Ca2+ levels in SH-SY5Y cells. Aggregates of
H2264–277, Nterm H2 extended259–277, H2 short265–272, and H2 very short268–272 (100 mM monomer concentration) were formed
at 3 different times (0, 1, and 15 h) and added to the cells for 60 min. The green fluorescence arises from the intracellular Fluo3
probe bound to Ca2+. The corresponding semiquantitative values of the green fluorescence signals are shown below the images.
The values shown are means 6 SEM of results in 3 independent experiments performed in triplicate. *P # 0.05, **P # 0.01,
***P # 0.001 vs. untreated cells, unless otherwise indicated.
Figure 9. Tht and CD assay analysis of NPM1-Cter-MutA. A) ThT fluorescence emission spectra in the presence of NPM1-
CterMutA (at 16 mM) registered at 0 and 12 h and 1, 2, 4, and 13 d. B) CD spectra recorded at 0, 2, 5, and 8 d at a concentration
of NPM1-CterMutA of 11 mM, with stirring.
NUCLEOPHOSMIN REGIONS FORM TOXIC AGGREGATES AT NEUTRAL PH 11
shown). Collectively, these considerations indicate that
the residual interactions involving H2 and stabilizing
its a-helical structure in the NPM1-CTD denatured
state prevent amyloidlike aggregation. It has been
shown that the stabilization of the a-helical struc-
ture can cause an acceleration of the aggregation
process, depending on the initial stability and location
of the a-helices (51). In particular, the effect can vary
if the stabilized helices are 1) in nonamyloidogenic
stretches of initially unstructured peptides (accelerat-
ing effect), 2) in amyloidogenic stretches of initially
unstructured peptides (no effect), or 3) in amyloido-
genic stretches of initially stable helices (decelerating
effect). Given the significant stability of H2 in the
denatured wt CTD and the observation that H2 is an
amyloidogenic stretch, the tendency of the wt CTD to
unfold throughcompact states retaining residuala-helical
structure may be a protective mechanism that prevents
unwanted and potentially harmful aggregation. There-
fore, not only folded states, but also compact unfolded
ones, are effective for escaping misfolding and aggre-
gation. It is also possible that the chaperone activity of
the N-terminal domain of NPM1 (16, 30), which has
stabilizing effects on the CTD (9), plays, among others,
a role in preventing themisfolding of NPM1-CTD in the
full-length protein.
Present findings may have implications for under-
standing AML-NPM1 mutants. Indeed, these mutants
present specific features (20, 52, 53): 1)mutations cause
the aberrant accumulation of NPM1 variants in the cy-
toplasm (NPM1c+); 2) mutated proteins acquire some
new properties (gain of function), along with expected
loss of protein functionality (loss of function); and 3)
mutations are common in adult AML (;30% of cases),
but occur less frequently in children (6.5–8.4%) (52). In
this scenario, the absence of strong intramolecular
interactions in the unfolded mutated CTDs and the
accumulation of the mutants into the cytoplasm may
favor aggregation through the exposure of the amyloi-
dogenic H2 region. The slow aggregation shown by
NPM1-Cter-MutA domain confirms our hypothesis. The
formation of cytoplasmic aggregates may, in turn, be
involved in the observed gain of function and in the
pathogenesis of the disease. Indeed, the observation
that H2 amyloidlike assemblies are cytotoxic suggests
that they are active biologic entities and that theymay be
involved in the gain of function observed in NPM1
mutants. It is worth mentioning that our data also show
that the H2 region of a rather rare exon 11 mutation,
which is associated with AML and characterized by a
prevalent nucleolar localization (37), has no tendency
to form amyloidlike aggregates, suggesting that a dif-
ferent pathogenic mechanism is at work in this case.
Nevertheless, it can be speculated that the lower accumu-
lation of this mutant into the cytoplasm (37) is somewhat
related to its inability to aggregate.
In conclusion, although a link between prionlike ag-
gregation and cancer has been proposed and currently
has been investigated only in p53 mutants (54), we be-
lieve that the possible link between aggregation of NPM1
andAML shouldbe seriously considered in studies aimed
at unveiling the molecular mechanisms of this severe,
widespread disease.
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